JP2017507943A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507943A5 JP2017507943A5 JP2016553897A JP2016553897A JP2017507943A5 JP 2017507943 A5 JP2017507943 A5 JP 2017507943A5 JP 2016553897 A JP2016553897 A JP 2016553897A JP 2016553897 A JP2016553897 A JP 2016553897A JP 2017507943 A5 JP2017507943 A5 JP 2017507943A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- neu
- osteosarcoma
- listeria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 32
- 101700025368 ERBB2 Proteins 0.000 claims description 26
- 102100016662 ERBB2 Human genes 0.000 claims description 26
- 101710037934 QRSL1 Proteins 0.000 claims description 26
- 241000186781 Listeria Species 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 108091006028 chimera Proteins 0.000 claims description 17
- 201000008968 osteosarcoma Diseases 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 230000002503 metabolic Effects 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 102000038129 antigens Human genes 0.000 claims description 10
- 108091007172 antigens Proteins 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 230000000240 adjuvant Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 241000282465 Canis Species 0.000 claims description 5
- 210000000349 Chromosomes Anatomy 0.000 claims description 4
- 230000001058 adult Effects 0.000 claims description 4
- 230000002238 attenuated Effects 0.000 claims description 4
- 150000008574 D-amino acids Chemical class 0.000 claims description 3
- 108010041525 EC 5.1.1.1 Proteins 0.000 claims description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 210000004898 N-terminal fragment Anatomy 0.000 claims description 3
- 229920000272 Oligonucleotide Polymers 0.000 claims description 3
- 102000004357 Transferases Human genes 0.000 claims description 3
- 108090000992 Transferases Proteins 0.000 claims description 3
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 230000003115 biocidal Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 230000002949 hemolytic Effects 0.000 claims description 3
- 229940035032 monophosphoryl lipid A Drugs 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 230000008506 pathogenesis Effects 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 230000017613 viral reproduction Effects 0.000 claims description 3
- 230000001018 virulence Effects 0.000 claims description 3
- 206010061289 Metastatic neoplasm Diseases 0.000 claims description 2
- 101700018766 ALR1 Proteins 0.000 claims 1
- 206010006007 Bone sarcoma Diseases 0.000 claims 1
- 241000220450 Cajanus cajan Species 0.000 claims 1
- 210000003414 Extremities Anatomy 0.000 claims 1
- 101710004784 GFER Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 101710028940 dadB Proteins 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000004927 fusion Effects 0.000 description 6
- 229960005486 vaccines Drugs 0.000 description 5
- 210000003169 Central Nervous System Anatomy 0.000 description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 description 4
- 230000000295 complement Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 206010017758 Gastric cancer Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
Description
一実施形態では、本明細書に提供される発明はHER2/neuを発現する腫瘍増殖またはガンを患う被験者内の転移性疾患を遅延する方法に関し、この方法は融合ポリペプチドをコードする核酸を含む組み換え型弱毒化リステリアを投与する工程を含み、前記融合ポリペプチドが追加的なポリペプチドに融合したHER2/neuキメラ抗原を含み、前記核酸分子が前記融合ポリペプチドをコードする第1のオープンリーディングフレームを含み、前記核酸分子が代謝酵素をコードする第2のオープンリーディングフレームをさらに含み、かつ前記代謝酵素が前記組み換え型リステリアワクチン株の染色体内で欠いている内因性遺伝子を相補する。別の実施形態では、被験者はヒトである。別の実施形態では、ヒトの被験者は大人であってもよく、または子どもであってもよい。別の実施形態では、被験者はイヌである。
本発明は、例えば、以下の項目を提供する。
(項目1)
被験者内のHER2/neuを発現する腫瘍増殖またはガンを治療する方法であって、前記方法が組み換え型ポリペプチドをコードする核酸を含む組み換え型弱毒化リステリアを含む組成物を投与する工程を含み、前記組み換え型ポリペプチドが追加的なポリペプチドに融合したHER2/neuキメラ抗原を含み、前記核酸分子が前記組み換え型ポリペプチドをコードする第1のオープンリーディングフレームを含み、前記核酸分子が代謝酵素をコードする第2のオープンリーディングフレームをさらに含み、かつ前記代謝酵素が前記組み換え型リステリア株の前記染色体内の突然変異した内因性遺伝子を相補する、方法。
(項目2)
前記組成物がリステリア約3.3×10 9 個のリステリア投与量を含む、項目1に記載の方法。
(項目3)
前記被験者がヒトまたはイヌの被験者である、項目1に記載の方法。
(項目4)
前記ヒトの被験者が子ども、青年、または大人である、項目3に記載の方法。
(項目5)
前記融合ポリペプチドを前記被験者に投与することが前記腫瘍の中のエスケープ変異を防止する、項目1に記載の方法。
(項目6)
前記HER2/neuキメラ抗原が前記マッピングしたヒトMHCクラスIエピトープのうちの少なくとも5、9、13、14、または17を含むヒトキメラ型HER2/neuである、項目1に記載の方法。
(項目7)
前記キメラ型HER2/neuがキメラ型イヌHER2/neuである、項目1に記載の方法。
(項目8)
前記核酸分子が前記リステリアゲノムに組み込まれる、項目1に記載の方法。
(項目9)
前記核酸分子が前記組み換え型リステリアワクチン株の中のプラスミドの中にあり、かつ抗生物質選択がないとき、前記プラスミドは前記組み換え型リステリアワクチン株の中に安定して維持される、項目1に記載の方法。
(項目10)
前記組み換え型リステリアが前記actA病毒性遺伝子内に突然変異を含む、項目1に記載の方法。
(項目11)
前記追加的なポリペプチドが、a)非溶血性LLOタンパク質もしくはN末端断片、b)PEST配列、またはc)ActA断片からなる群から選択される、項目1に記載の方法。
(項目12)
前記第2のオープンリーディングフレームによってコードされた前記代謝酵素がアラニン・ラセマーゼ酵素またはD−アミノ酸トランスフェラーゼ酵素である、項目1に記載の方法。
(項目13)
独立したアジュバントをさらに含む、項目1に記載の方法。
(項目14)
前記アジュバントが、顆粒球性/マクロファージコロニー刺激因子(GM−CSF)タンパク質、GM−CSFタンパク質をコードするヌクレオチド分子、サポニンQS21、モノホスホリルリピドA、またはメチル化されていないCpG含有オリゴヌクレオチドを含む、項目12に記載の方法。
(項目15)
前記腫瘍がHER2/neu陽性腫瘍であり、かつ前記ガンがHER2/neuを発現するガンである、項目1に記載の方法。
(項目16)
前記ガンが骨肉腫、卵巣ガン、胃ガン、中枢神経系(CNS)のガン、またはユーイング肉腫(ES)である、項目1に記載の方法。
(項目17)
前記骨肉腫ガンがイヌの骨肉腫である、項目16に記載の方法。
(項目18)
前記骨肉腫が小児骨肉腫である、項目16に記載の方法。
(項目19)
被験者内のHER2/neuを発現する腫瘍増殖またはガンに対する強化した免疫応答を引き出す方法であって、前記方法が組み換え型ポリペプチドをコードする核酸を含む組み換え型弱毒化リステリア株を含む組成物を投与する工程を含み、前記融合ポリペプチドが追加的なポリペプチドに融合したHER2/neuキメラ抗原を含み、前記核酸分子が前記組み換え型ポリペプチドをコードする第1のオープンリーディングフレームを含み、前記核酸分子が代謝酵素をコードする第2のオープンリーディングフレームをさらに含み、かつ前記代謝酵素が前記組み換え型リステリア株の前記染色体内の突然変異した内因性遺伝子を相補する、方法。
(項目20)
前記組成物がリステリア約3.3×10 9 個のリステリア投与量を含む、項目1に記載の方法。
(項目21)
前記被験者がヒトまたはイヌの被験者である、項目19に記載の方法。
(項目22)
前記ヒトの被験者が子ども、青年、または大人である、項目21に記載の方法。
(項目23)
前記融合ポリペプチドをHER2/neuを発現する腫瘍を有する前記被験者に投与することが前記腫瘍の中のエスケープ変異を防止する、項目19に記載の方法。
(項目24)
前記HER2/neuキメラ抗原が前記マッピングしたヒトMHCクラスIエピトープのうちの少なくとも5、9、13、14、または17を含むヒトキメラ型HER2/neuである、項目19に記載の方法。
(項目25)
前記キメラ型HER2/neuがキメラ型イヌHER2/neuである、項目19に記載の方法。
(項目26)
前記核酸分子が前記リステリアゲノムに組み込まれる、項目19に記載の方法。
(項目27)
核酸分子が、前記組み換え型リステリアワクチン株の中のプラスミド内にある、項目19に記載の方法。
(項目28)
抗生物質選択が無いときに前記プラスミドが前記組み換え型リステリアワクチン株内で安定して維持される、項目19に記載の方法。
(項目29)
前記組み換え型リステリアが前記actA病毒性遺伝子内に突然変異を含む、項目19に記載の方法。
(項目30)
前記追加的なポリペプチドが、a)非溶血性LLOタンパク質もしくはN末端断片、b)PEST配列、またはc)ActA断片からなる群から選択される、項目19に記載の方法。
(項目31)
前記第2のオープンリーディングフレームによってコードされた前記代謝酵素がアラニン・ラセマーゼ酵素またはD−アミノ酸トランスフェラーゼ酵素である、項目19に記載の方法。
(項目32)
独立したアジュバントをさらに含む、項目19に記載の方法。
(項目33)
前記アジュバントが、顆粒球性/マクロファージコロニー刺激因子(GM−CSF)タンパク質、GM−CSFタンパク質をコードするヌクレオチド分子、サポニンQS21、モノホスホリルリピドA、またはメチル化されていないCpG含有オリゴヌクレオチドを含む、項目32に記載の方法。
(項目34)
前記腫瘍がHER2/neu陽性腫瘍であり、かつ前記ガンがHER2/neuを発現するガンである、項目19に記載の方法。
(項目35)
前記ガンが骨肉腫、卵巣ガン、胃ガン、中枢神経系(CNS)のガン、またはユーイング肉腫(ES)である、項目19に記載の方法。
(項目36)
前記骨肉腫ガンがイヌの骨肉腫である、項目35に記載の方法。
(項目37)
前記骨肉腫が小児骨肉腫である、項目19に記載の方法。
(項目38)
前記HER2/neuを発現する腫瘍またはガンに対する前記免疫応答が、前記HER2/neuタンパク質の準優占エピトープへの免疫応答を含む、項目19に記載の方法。
In one embodiment, the invention provided herein relates to a method of delaying metastatic disease in a subject suffering from tumor growth or cancer that expresses HER2 / neu, the method comprising a nucleic acid encoding a fusion polypeptide. Administering a recombinant attenuated Listeria, wherein said fusion polypeptide comprises a HER2 / neu chimeric antigen fused to an additional polypeptide, wherein said nucleic acid molecule encodes said fusion polypeptide The nucleic acid molecule further comprises a second open reading frame encoding a metabolic enzyme, and the metabolic enzyme complements an endogenous gene that is lacking in the chromosome of the recombinant Listeria vaccine strain. In another embodiment, the subject is a human. In another embodiment, the human subject may be an adult or a child. In another embodiment, the subject is a dog.
For example, the present invention provides the following items.
(Item 1)
A method of treating tumor growth or cancer expressing HER2 / neu in a subject comprising administering a composition comprising a recombinant attenuated Listeria comprising a nucleic acid encoding a recombinant polypeptide, The recombinant polypeptide comprises a HER2 / neu chimeric antigen fused to an additional polypeptide, the nucleic acid molecule comprises a first open reading frame encoding the recombinant polypeptide, and the nucleic acid molecule comprises a metabolic enzyme; A method further comprising a second open reading frame encoding, and wherein said metabolic enzyme complements a mutated endogenous gene in said chromosome of said recombinant Listeria strain.
(Item 2)
The method of claim 1, wherein the composition comprises a dose of about 3.3 × 10 9 Listeria.
(Item 3)
Item 2. The method according to Item 1, wherein the subject is a human or dog subject.
(Item 4)
4. The method of item 3, wherein the human subject is a child, adolescent or adult.
(Item 5)
The method of item 1, wherein administering the fusion polypeptide to the subject prevents escape mutations in the tumor.
(Item 6)
The method of item 1, wherein the HER2 / neu chimeric antigen is a human chimeric HER2 / neu comprising at least 5, 9, 13, 14, or 17 of the mapped human MHC class I epitopes.
(Item 7)
Item 2. The method according to Item 1, wherein the chimeric HER2 / neu is a chimeric dog HER2 / neu.
(Item 8)
Item 2. The method according to Item 1, wherein the nucleic acid molecule is integrated into the Listeria genome.
(Item 9)
Item 1. The nucleic acid molecule is in a plasmid in the recombinant Listeria vaccine strain and when there is no antibiotic selection, the plasmid is stably maintained in the recombinant Listeria vaccine strain. the method of.
(Item 10)
The method according to item 1, wherein the recombinant Listeria comprises a mutation in the actA disease virulence gene.
(Item 11)
2. The method of item 1, wherein the additional polypeptide is selected from the group consisting of a) a non-hemolytic LLO protein or N-terminal fragment, b) a PEST sequence, or c) an ActA fragment.
(Item 12)
The method according to item 1, wherein the metabolic enzyme encoded by the second open reading frame is an alanine racemase enzyme or a D-amino acid transferase enzyme.
(Item 13)
The method of item 1, further comprising an independent adjuvant.
(Item 14)
The adjuvant comprises granulocytic / macrophage colony stimulating factor (GM-CSF) protein, nucleotide molecule encoding GM-CSF protein, saponin QS21, monophosphoryl lipid A, or unmethylated CpG-containing oligonucleotide, 13. The method according to item 12.
(Item 15)
Item 2. The method according to Item 1, wherein the tumor is a HER2 / neu positive tumor and the cancer is a cancer that expresses HER2 / neu.
(Item 16)
2. The method of item 1, wherein the cancer is osteosarcoma, ovarian cancer, gastric cancer, central nervous system (CNS) cancer, or Ewing sarcoma (ES).
(Item 17)
The method according to item 16, wherein the osteosarcoma cancer is canine osteosarcoma.
(Item 18)
The method according to item 16, wherein the osteosarcoma is childhood osteosarcoma.
(Item 19)
Administration of a composition comprising a recombinant attenuated Listeria strain comprising a nucleic acid encoding a recombinant polypeptide, wherein the method elicits an enhanced immune response against tumor growth or cancer expressing HER2 / neu in a subject And wherein said fusion polypeptide comprises a HER2 / neu chimeric antigen fused to an additional polypeptide, said nucleic acid molecule comprising a first open reading frame encoding said recombinant polypeptide, and said nucleic acid molecule Further comprising a second open reading frame encoding a metabolic enzyme, and the metabolic enzyme complements a mutated endogenous gene in the chromosome of the recombinant Listeria strain.
(Item 20)
The method of claim 1, wherein the composition comprises a dose of about 3.3 × 10 9 Listeria.
(Item 21)
20. A method according to item 19, wherein the subject is a human or dog subject.
(Item 22)
22. A method according to item 21, wherein the human subject is a child, adolescent or adult.
(Item 23)
20. The method of item 19, wherein administering the fusion polypeptide to the subject having a tumor that expresses HER2 / neu prevents escape mutations in the tumor.
(Item 24)
20. The method of item 19, wherein the HER2 / neu chimeric antigen is a human chimeric HER2 / neu comprising at least 5, 9, 13, 14, or 17 of the mapped human MHC class I epitopes.
(Item 25)
Item 20. The method according to Item 19, wherein the chimeric HER2 / neu is a chimeric dog HER2 / neu.
(Item 26)
20. A method according to item 19, wherein the nucleic acid molecule is integrated into the Listeria genome.
(Item 27)
20. A method according to item 19, wherein the nucleic acid molecule is in a plasmid in the recombinant Listeria vaccine strain.
(Item 28)
20. A method according to item 19, wherein the plasmid is stably maintained in the recombinant Listeria vaccine strain in the absence of antibiotic selection.
(Item 29)
20. The method of item 19, wherein the recombinant Listeria comprises a mutation in the actA disease virulence gene.
(Item 30)
20. The method of item 19, wherein the additional polypeptide is selected from the group consisting of a) a non-hemolytic LLO protein or N-terminal fragment, b) a PEST sequence, or c) an ActA fragment.
(Item 31)
20. A method according to item 19, wherein the metabolic enzyme encoded by the second open reading frame is an alanine racemase enzyme or a D-amino acid transferase enzyme.
(Item 32)
20. A method according to item 19, further comprising an independent adjuvant.
(Item 33)
The adjuvant comprises granulocytic / macrophage colony stimulating factor (GM-CSF) protein, nucleotide molecule encoding GM-CSF protein, saponin QS21, monophosphoryl lipid A, or unmethylated CpG-containing oligonucleotide, 33. A method according to item 32.
(Item 34)
20. The method according to item 19, wherein the tumor is a HER2 / neu positive tumor and the cancer is a cancer that expresses HER2 / neu.
(Item 35)
20. The method of item 19, wherein the cancer is osteosarcoma, ovarian cancer, gastric cancer, central nervous system (CNS) cancer, or Ewing sarcoma (ES).
(Item 36)
36. The method of item 35, wherein the osteosarcoma cancer is canine osteosarcoma.
(Item 37)
20. A method according to item 19, wherein the osteosarcoma is childhood osteosarcoma.
(Item 38)
20. The method of item 19, wherein the immune response to the HER2 / neu expressing tumor or cancer comprises an immune response to a quasi-dominant epitope of the HER2 / neu protein.
Claims (20)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/189,008 | 2014-02-25 | ||
US14/189,008 US20150366955A9 (en) | 2009-11-11 | 2014-02-25 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
US14/268,436 US20140234370A1 (en) | 2009-11-11 | 2014-05-02 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
US14/268,436 | 2014-05-02 | ||
US201462076411P | 2014-11-06 | 2014-11-06 | |
US62/076,411 | 2014-11-06 | ||
PCT/US2015/017559 WO2015130810A2 (en) | 2014-02-25 | 2015-02-25 | Compositions and methods for the treatment of her2/neu over-expressing tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017507943A JP2017507943A (en) | 2017-03-23 |
JP2017507943A5 true JP2017507943A5 (en) | 2018-08-02 |
Family
ID=54009773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016553897A Pending JP2017507943A (en) | 2014-02-25 | 2015-02-25 | Compositions and methods for the treatment of HER2 / NEU overexpressing tumors |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP3110942A4 (en) |
JP (1) | JP2017507943A (en) |
KR (2) | KR20160122829A (en) |
CN (1) | CN106661538A (en) |
AU (1) | AU2015223136A1 (en) |
BR (1) | BR112016019534A2 (en) |
CA (1) | CA2940646A1 (en) |
IL (1) | IL247436A0 (en) |
MX (1) | MX2016011114A (en) |
NZ (1) | NZ723750A (en) |
RU (1) | RU2016137834A (en) |
SG (1) | SG11201607036XA (en) |
WO (1) | WO2015130810A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
EP2683400A4 (en) | 2011-03-11 | 2014-09-17 | Advaxis | Listeria-based adjuvants |
SG11201405605VA (en) | 2012-03-12 | 2014-10-30 | Advaxis Inc | SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT |
CA2947358A1 (en) | 2014-02-18 | 2015-08-27 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
KR20160132033A (en) * | 2014-03-05 | 2016-11-16 | 어드박시스, 인크. | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio |
KR102359691B1 (en) | 2014-04-24 | 2022-02-10 | 어드박시스, 인크. | Recombinant listeria vaccine strains and methods of producing the same |
MA41644A (en) | 2015-03-03 | 2018-01-09 | Advaxis Inc | LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF |
AU2016369519B2 (en) | 2015-12-16 | 2023-04-20 | Gritstone Bio, Inc. | Neoantigen identification, manufacture, and use |
MX2019005685A (en) | 2016-11-30 | 2019-09-04 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof. |
KR20200044982A (en) | 2017-09-19 | 2020-04-29 | 어드박시스, 인크. | Composition and method for lyophilization of bacteria or Listeria strains |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6855320B2 (en) * | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
-
2015
- 2015-02-25 BR BR112016019534A patent/BR112016019534A2/en not_active Application Discontinuation
- 2015-02-25 NZ NZ723750A patent/NZ723750A/en unknown
- 2015-02-25 AU AU2015223136A patent/AU2015223136A1/en not_active Abandoned
- 2015-02-25 KR KR1020167025517A patent/KR20160122829A/en not_active IP Right Cessation
- 2015-02-25 EP EP15755609.3A patent/EP3110942A4/en not_active Withdrawn
- 2015-02-25 WO PCT/US2015/017559 patent/WO2015130810A2/en active Application Filing
- 2015-02-25 KR KR1020247007406A patent/KR20240038103A/en active Search and Examination
- 2015-02-25 CA CA2940646A patent/CA2940646A1/en active Pending
- 2015-02-25 RU RU2016137834A patent/RU2016137834A/en not_active Application Discontinuation
- 2015-02-25 JP JP2016553897A patent/JP2017507943A/en active Pending
- 2015-02-25 SG SG11201607036XA patent/SG11201607036XA/en unknown
- 2015-02-25 CN CN201580010568.4A patent/CN106661538A/en active Pending
- 2015-02-25 MX MX2016011114A patent/MX2016011114A/en unknown
-
2016
- 2016-08-23 IL IL247436A patent/IL247436A0/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017507943A5 (en) | ||
JP2013526837A5 (en) | ||
RU2016137834A (en) | COMPOSITIONS AND METHODS FOR TREATING TUMORS SUPERPRESSING HER2 / neu | |
US9969986B2 (en) | Virus like particle comprising modified envelope protein E3 | |
JP2017195888A5 (en) | ||
US10526387B2 (en) | Tumor vaccination involving a humoral immune response against self-proteins | |
JP2017513502A5 (en) | ||
JP2016202185A (en) | Homodimeric protein constructs | |
JP2018508212A5 (en) | ||
JP2016156828A5 (en) | ||
KR20170092626A (en) | Combination therapies with recombinant listeria strains | |
US20160200775A1 (en) | Virus like particle comprising modified envelope protein e3 | |
JP6406647B2 (en) | Cellular immunity induction vaccine | |
AU2017211387A1 (en) | Personalized delivery vector-based immunotherapy and uses thereof | |
KR20230004585A (en) | Anti-cancer vaccine for individualized therapy | |
Fioretti et al. | Recent advances in design of immunogenic and effective naked DNA vaccines against cancer | |
WO2017175253A1 (en) | Exosome-targeted dna vaccine | |
Bolhassani et al. | Small heat shock proteins B1 and B6: Which one is the most effective adjuvant in therapeutic HPV vaccine? | |
Andreasson et al. | Murine pneumotropic virus chimeric Her2/neu virus‐like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors | |
EP2366709A1 (en) | Tumor vaccination involving a humoral immune response against self-proteins | |
JP2020526202A5 (en) | ||
JPWO2020097393A5 (en) | ||
US11844824B2 (en) | Nucleic acid molecules and methods of using the same | |
JP2024054375A (en) | Exosome-targeted DNA vaccine | |
CN117915940A (en) | Vaccine compositions comprising encoded adjuvants |